While their efficacy in resolving metabolic dysfunction-associated steatohepatitis (MASH) is increasingly well documented, their ability to target the metabolic hepatic nexus also suggests a promising therapeutic role in ALD and MetALD
Regarding acute toxicity, according to the 2023 National Poison Data System annual report, there were 7905 reported unintentional heavy metal exposures in the United States, resulting in 26 serious health outcomes and two deaths
About 9% and 6% were on sulfonylureas and GLP-1R agonists, respectively, while less than 5% were on DPP-4 and SGLT2 inhibitors, respectively
The main difference between the two is the dose, since they are the same drug (semaglutide) and you take them in the same way
It still runs, just less smoothly